Teva’s Austedo Positioned To Compete With A Generic Rival
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.
You may also be interested in...
Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.
Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.
Impending clinical trial readouts will indicate whether pharmaceutical companies are on the right track to develop new investigational agents against the cause of the neurodegenerative disorder, Huntington's disease.